Amgen Inc Price Target Raised at RBC Capital 
<p>Analysts at RBC Capital raised their price target on <a href='https://financialmodelingprep.com/financial-summary/AMGN'>Amgen Inc. (NASDAQ:AMGN) </a>to $218 from $216, maintaining their sector perform rating to reflect the early approval of Tezspire (tezepelumab) into severe asthma & Otezla’s label expansion into mild-to-moderate plaque psoriasis. </p>
<p>The analysts see both approvals as notable with Tezspire’s broad label making it the only biologic without phenotype or biomarker limitations and Otezla’s label expansion to include mild-to-moderate plaque psoriasis patients making it the first and only oral therapy indicated across all psoriasis severity levels. </p>

NASDAQ:AMGN